Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy

• Published in: Ocular immunology and inflammation Vol. 30; no. 7-8; pp. 1833 - 1841
• Main Authors: Gozzi, Fabrizio, Aldigeri, Raffaella, Mastrofilippo, Valentina, De Simone, Luca, Bolletta, Elena, Marzano, Jacopo, Iannetta, Danilo, Coassin, Marco, Ilariucci, Fiorella, Ferrari, Angela, Luminari, Stefano, Merli, Francesco, Croci, Stefania, Zerbini, Alessandro, Farnetti, Enrico, Nicoli, Davide, Valli, Riccardo, Tamagnini, Ione, Cavazza, Alberto, Salvarani, Carlo, Fontana, Luigi, Cimino, Luca
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 17.11.2022
• Subjects: chemotherapy; CNS involvement; Humans; Lymphoma - diagnosis; Lymphoma - drug therapy; Retinal Neoplasms - diagnosis; Retinal Neoplasms - drug therapy; Retrospective Studies; survival; Uveitis; uveitis masquerade syndrome; Vitreoretinal lymphoma; Vitreous Body; CNS involvement; Vitreoretinal lymphoma; chemotherapy; uveitis masquerade syndrome; survival
• ISSN: 0927-3948; 1744-5078
• DOI: 10.1080/09273948.2021.1962916

To investigate the role of combined systemic and local chemotherapy in improving the survival of patients with vitreoretinal lymphoma (VRL). Patients with VRL consecutively seen from 2006 to 2020 were retrospectively reviewed; data on the presence and time of central nervous system (CNS) involvement and treatment regimen (systemic, local or combined chemotherapy) were collected. Overall survival (OS) and progression-free survival (PFS) were calculated for each group. Forty-three eyes of 22 subjects with histology-proven VRL were included. Mean time of survival was 64.8 months (SE±10.8). Twelve patients (57%) presented CNS involvement, which was significantly associated with progression (r = 0.48, P = .03) and death (r = 0.56, P = .009). The isolated primary VRL group had a 5-year OS of 80%. Combined systemic and local chemotherapy reduced the risk of death by 82% (hazard ratio 0.18[0.04- 0.85]) in the entire cohort. Combined systemic and local chemotherapy significantly improved OS but not PFS of patients affected by VRL.